Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Letter from the Editor
Steve and I just got to New Orleans in time for the opening of the ADA Scientific Sessions, and already it looks like we are going to garner a lot of diabetes information in a short amount of time. As I was working on ideas for reporting, I noticed that there are over 2,100 poster presentations, with over 150 on the SGLT-2 Inhibitors alone. We figured there would be a lot of buzz due to the positive heart effects of Jardiance, and it looks like the others will be following suit. There is also some information on implantable sensors, and this concept got a real push this week as the European Union approved the first implantable sensor (see item 4). The interesting thing is that they are not even a company you have heard of. We are looking forward to getting to the thought leaders in all these categories, and getting the inside scoop that only we at Diabetes In Control can.
Announcements:
dLifeTV.com: Sunday, June 12, 7PM ET
From dLife.com: “Charlie O’Connell talks about exercise and the Dawn Phenomenon; Chef Michel Nischan cooks up some grilled shrimp and eggplant; Jim Turner talks with other people living with diabetes about how every day is tough; Golfer Michelle McGann shares her experience with living with diabetes.” Sundays live online at dLifeTV.com at 7 PM ET, 6 PM CT, and 4 PM PT. Keep up on the latest dLife news at dLifeTV.com.
*****************************
We can make a difference!
*****************************
Dave Joffe, Editor-in-chief
This Week's Survey
Do you prefer to watch our video interviews with recognized diabetes doctors and experts, or read transcriptions of the interviews?
1) Videos
2) Transcripts
3) Both
Please let us know — follow the link to respond!
Tool for Your Practice
This chart provides carbohydrates and calories per volume for common alcoholic beverages, including beer, wine, and mixed drinks.
Test Your Knowledge
The list below indicates the ethnicities of the patients whose cases you have just reviewed over the past month. Please choose the correct order showing the relative risk of developing diabetes for each ethnicity in adults 20 years and older.
Select one answer:
[A] Non-Hispanic blacks, Hispanic, non-Hispanic whites, Asian American
[B] Hispanic, Non-Hispanic blacks, non-Hispanic whites, Asian American
[C] Non-Hispanic blacks, Hispanic, Asian American, non-Hispanic whites
[D] Hispanic , Non-Hispanic blacks, Asian American, non-Hispanic whites
Are you right? Follow the link to respond!
Did You Know: NICE Backs Freer Use of SGLT-2 Inhibitors
The National Institute of Health and Care Excellence (NICE) has recommended that SGLT-2 inhibitors on the UK market can be used earlier in patients with diabetes. The new guidance allows the drugs to be used first-line for people who cannot tolerate metformin, and in whom sulfonylureas or Actos (pioglitazone) are not considered appropriate. More importantly, the recommendations put the SGLT-2 inhibitors on par with another newer class of diabetes drug — DPP-4 inhibitors such as MSD’s Januvia (sitagliptin) and AstraZeneca’s Onglyza (saxagliptin). The guidance applies to Johnson & Johnson’s Invokana (canagliflozin), AstraZeneca’s Farxiga (dapagliflozin) and Boehringer Ingelheim/Eli Lilly’s Jardiance (empagliflozin). Previously, NICE guidance only backed use of the drugs in combination with metformin, either alone or in combination with a sulfonylurea or insulin, but now the recommendations allow clinicians “the freedom to prescribe SGLT-2 inhibitors when they feel it is appropriate.” While the growth of the SGLT-2 inhibitor class has been held back somewhat by safety concerns such as ketoacidosis, data published last year on Jardiance showing it was able to lower cardiovascular risk — the first diabetes drug to do so — has reinforced confidence in the class. — Recommendation positions Invokana, Farxiga and Jardiance as first-line treatments
Elevated 1-hour level proves significant despite 2-hour level within normal glucose tolerance range.
Exercise shown to have some AFib-specific benefits.
Harvard researchers find as many as 40 percent of cancer cases, and half of cancer deaths, come down to things people could easily change.
Senseonics’ Eversense™ 90-day implantable CGM approved in Europe.
Study suggests wine consumption offers greater protection against type 2 risk, compared with beer or other alcoholic beverages.
Large observational study using real-world data finds no increased risk for hospitalized heart failure (hHF) among patients who initiated use of DPP-4 inhibitors, compared to other antihyperglycemics.
Quote of the Week!
“Physical fitness is not only one of the most important keys to a healthy body, it is the basis of dynamic and creative intellectual activity.”
…John F. Kennedy
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com